Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gamida Cell Ltd. - Ordinary Shares (NQ:GMDA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gamida Cell Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference
From Gamida Cell Ltd.
Via Business Wire
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Gamida Cell Posts Updated Omidubicel Data In Blood Cancer Patients
 
Via Benzinga
Gamida Cell Shares Jump On FDA Nod To Cell Therapy Trial In Blood Cancer Settings
 
Via Benzinga
Gamida Cell: Q4 Earnings Insights
Gamida Cell (NASDAQ:GMDA) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Gamida Cell: Q1 Earnings Insights
Gamida Cell (NASDAQ:GMDA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Gamida Cell reported in-line EPS of... 
Via Benzinga
Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
Earnings Preview: Gamida Cell
Gamida Cell (NASDAQ:GMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Gamida Cell will... 
Via Benzinga
Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022
From Gamida Cell Ltd.
Via Business Wire
Cell Therapy-Focused Gamida Plans To Cut 10% Of Staff
Gamida Cell Ltd (NASDAQ: GMDA) will terminat 
Via Benzinga
Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
From Gamida Cell Ltd.
Via Business Wire
The Daily Biotech Pulse - Tuesday, April,26
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201
From Gamida Cell
Via Business Wire
Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference
From Gamida Cell Ltd.
Via Business Wire
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Gamida Cell Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
Earnings Scheduled For March 15, 2022
Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi... 
Via Benzinga
Preview: Gamida Cell's Earnings
Gamida Cell (NASDAQ:GMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-15. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
Merck (MRK) Outperforms Industry, What's In Store For 2022?
Merck boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales. 
Via Talk Markets
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Gamida Cell Shares Surge On Rolling Omidubicel Marketing Application In US
Gamida Cell Ltd (NASDAQ: GMDA) has initiated the Biologics License Application (BLA)  
Via Benzinga
Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces Appointment of Anat Cohen-Dayag and Naama Halevi-Davidov to its Board of Directors
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Provides Key Program Updates and 2022 Financial Guidance
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Ltd. (NASDAQ:GMDA) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 01/27/2022 -- Certain directors of Gamida Cell Ltd are under investigation over potential breaches of fiduciary duties. 
Via SBWire
48 Biggest Movers From Yesterday
Gainers Aptorum Group Limited (NYSE: APM) shares jumped 38.5% to close at $1.69 on Thursday after the company announced it received FDA Orphan Drug designation for... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.